Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells

Basit Öğe Kaydı
dc.contributor.authorKüçükcankurt, F.
dc.contributor.authorUçak, S.
dc.contributor.authorAltiok, N.
dc.date.accessioned2024-05-19T14:33:21Z
dc.date.available2024-05-19T14:33:21Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground/aim: The overexpression of HER2 is correlated with poorer outcomes and therapeutic resistance in breast cancer patients. While HER2-targeted therapies have shown improvement, prognosis remains poor for HER2-positive breast cancer patients, and these treatments have limitations. Therefore, it is crucial to explore effective molecular strategies for early detection and treatment of HER2-positive breast cancers. Materials and methods: In this study, we employed the cell-SELEX method to generate a selective aptamer capable of recognizing HER2 in its native conformation within breast cancer cells, for theranostic applications. Utilizing an adherent cell-SELEX approach, we developed and explored a DNA aptamer, named HMAP7, which can specifically target HER2 in the MDA-MB-453 and SK-BR-3 human breast cancer cell lines. After sequencing, the binding affinities of 10 candidate aptamers to HER2 receptors were evaluated by measuring fluorescence intensities within intact cells using near-infrared optical imaging. The dissociation constant of HMAP7 was determined to be in the nanomolar range in both cell lines. Results: The cell-SELEX-derived aptamer sequence, HMAP7 (41-mer), exhibited the highest binding affinity and specificity for HER2. HMAP7 was rapidly internalized into breast cancer cells overexpressing HER2 but showed no uptake in the HER2 receptor-deficient breast cancer cell line MDA-MB-231. Moreover, HMAP7 demonstrated remarkable selectivity for HER2, rendering it suitable for use in complex biological systems. Conclusions: Our findings suggest that the novel DNA aptamer HMAP7 holds promise for both therapeutic and diagnostic applications, enabling selective delivery of therapeutic agents or imaging of HER2-positive breast tumors. © 2024, TUBITAK. All rights reserved.en_US
dc.description.sponsorshipTürkiye Bilimsel ve Teknolojik Araştırma Kurumu, TÜBİTAK: 114S517en_US
dc.description.sponsorshipThese studies were funded by The Scientific and Technological Research Council of Türkiye (TÜBİTAK) project 114S517.en_US
dc.identifier.doi10.55730/1300-0152.2680
dc.identifier.endpage45en_US
dc.identifier.issn1300-0152
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85186550133en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage35en_US
dc.identifier.urihttps://doi.org/10.55730/1300-0152.2680
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4203
dc.identifier.volume48en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTUBITAKen_US
dc.relation.ispartofTurkish Journal of Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAptameren_US
dc.subjectBreast Canceren_US
dc.subjectCell-Selexen_US
dc.subjectHer2en_US
dc.subjectOptical İmagingen_US
dc.subjectTargeted Therapyen_US
dc.titleTheranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cellsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu